Showing 11 posts of 11 posts found.


New Year, new goals

February 8, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CRUK, Cancer Research UK, Chiesi, EMA, FDA, Genetic Alliance, pharma

With the New Year begun in earnest, Pharmafocus speaks to a range of players in pharma and the life sciences …


EMA committee recommends seven therapies from Roche, GSK, MSD and more

January 29, 2018
Sales and Marketing Biocon, Chiesi, Chugai, GSK, GlaxoSmithKline, MSD, Mylan, Roche, Sanofi, pharma

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has voiced its recommendation of a raft of …


Chiesi set to acquire Medicine Co cardiovascular assets, say reports

May 9, 2016
Sales and Marketing Chiesi, assets, cardiovascular, medicine co

Italian pharmaceutical company Chiesi are set to expand their global footprint as it nears an agreement to acquire Medicines Co’s …

Chiesi image

Chiesi rapped for ABPI code breach

May 7, 2015
Medical Communications, Sales and Marketing ABPI, Chiesi, PMCPA

Chiesi made its sales reps go through a ‘tick-box’ compliance training exercise to get the pharma industry regulator ‘off its …

Chiesi image

Chiesi reprimanded again over Fostair drug

March 3, 2015
Manufacturing and Production, Medical Communications, Sales and Marketing ABPI, Chiesi, PMCPA, code, formoterol/beclometason, fostair

Chiesi has been reprimanded after it breached the ABPI’s Code of Practice for its promotion of asthma inhaler Fostair. The …

Chiesi image

Chiesi’s stem cell therapy approved in Europe

February 23, 2015
Research and Development, Sales and Marketing Chiesi, EC, Europe, Holoclar, Holostem Advanced Therapies, LSCD, stem cell

Chiesi’s Holoclar has become the first stem cell therapy to get the green light in Europe, gaining conditional approval from …

Chiesi gets first-ever European stem cell nod

December 19, 2014
Sales and Marketing Chiese, Chiesi, EMA, Holoclar, LSCD, MHRA, Stem cells, orexigen

Chiesi has received the first approval for an advanced therapy medicinal product containing stem cells for use in Europe. The …

Chiesi image

Chiesi publicly reprimanded

December 13, 2013
Sales and Marketing ABPI, Chiesi, PMCPA, fostair

Chiesi has had the book thrown at it by the PMCPA and faces the shame of a public reprimand – …

Chiesi image

Chiesi snaps up Zymenex

August 29, 2013
Sales and Marketing Chiesi, lamazym, rare diseases, zymenex

Chiesi Group is to acquire biopharma company Zymenex Holdings, allowing the Italian firm to enter the rare disease arena for …

PMCPA reprimands Chiesi for multiple breaches

June 18, 2012
Sales and Marketing COPD, Chiesi, GSK, PMCPA, code

Chiesi has been publicly reprimanded by the PMCPA part for promoting its asthma drug Fostair off-label. The embarrassing slapdown from …

Chiesi breaks ground on new R&D headquarters in Palma

July 13, 2009
Research and Development Chiesi, Europe, Italy

Construction of Chiesi's new 70 million euro centre for research and development has begun in Parma, Italy. The Italian company …

Latest content